Although we found that in vivo modulator use coincided with significantly lower transferrin (P = 0.0076) in activated, modulator-pretreated CF MDMs (Supplementary Fig. S3g), TfR1 protein expression was not altered in association with patient modulator use under any treatment conditions (Supplementary Fig. S4a,b). The gene discussed is TF; the disease is cystic fibrosis.